MicuRx is a multi-asset clinical stage company biotech company focusing on improving the quality of life for patients with rare chronic pulmonary diseases. The lead asset MRX-5 has completed phase 1 for MABC nontuberculous mycobacteria pulmonary disease, a rare lung disease that currently has no approved treatment. Novel MOA, potential first-in-class. Target Orphan Drug, Fast Track and QIDP Designations.